Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.50 |
| ▸ | HBB | P68871 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177144 | 0.86 | SMN1; SMN2 (0.54) | NOS3NOS1NOS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL20931741 | 0.85 | MEN1 (0.52) | SMN1; SMN2ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL28015509 | 0.83 | CCR1 (0.48) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL19877778 | 0.83 | CCR1 (0.48) | NOS3NOS1NOS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL28350627 | 0.82 | LOXL2 (0.56) | NOS3NOS1NOS2SMN1; SMN2ALDH1A1 | |
| SCHEMBL24135708 | 0.80 | PARP10 (0.61) | ALDH1A1KMT2AKDM4ELOXL2LOX | |
| SCHEMBL19877732 | 0.78 | LOXL2 (0.62) | SMN1; SMN2ALDH1A1KDM4ECCR1CCR5 | |
| SCHEMBL1644458 | 0.77 | MAPT (0.52) | SMN1; SMN2ALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL1206676 | 0.77 | CCR1 (0.64) | NOS3NOS1NOS2ALDH1A1CCR1 | |
| SCHEMBL177968 | 0.75 | KDM4E (0.61) | SMN1; SMN2ALDH1A1TDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1337513-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036570-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | NOS3 814/4885NOS1 1018/4885NOS2 1187/4885 |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | NQO2, TPD52L2, MLX | NOS3 473/4885NOS1 404/4885NOS2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.